Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
CRMD's Cash-to-Debt is ranked higher than
83% of the 982 Companies
in the Global Biotechnology industry.

( Industry Median: 37.83 vs. CRMD: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CRMD' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.11  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.74
CRMD's Equity-to-Asset is ranked higher than
58% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. CRMD: 0.74 )
Ranked among companies with meaningful Equity-to-Asset only.
CRMD' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.36  Med: 0.81 Max: 0.95
Current: 0.74
-1.36
0.95
Piotroski F-Score: 3
Altman Z-Score: -13.04
Beneish M-Score: -4.83
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -12608.97
CRMD's Operating Margin % is ranked lower than
93% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -93.92 vs. CRMD: -12608.97 )
Ranked among companies with meaningful Operating Margin % only.
CRMD' s Operating Margin % Range Over the Past 10 Years
Min: -245750  Med: -9492.25 Max: -4710.05
Current: -12608.97
-245750
-4710.05
Net Margin % -12560.09
CRMD's Net Margin % is ranked lower than
93% of the 760 Companies
in the Global Biotechnology industry.

( Industry Median: -84.10 vs. CRMD: -12560.09 )
Ranked among companies with meaningful Net Margin % only.
CRMD' s Net Margin % Range Over the Past 10 Years
Min: -456650  Med: -10911.74 Max: -8660.95
Current: -12560.09
-456650
-8660.95
ROE % -125.91
CRMD's ROE % is ranked lower than
83% of the 906 Companies
in the Global Biotechnology industry.

( Industry Median: -37.24 vs. CRMD: -125.91 )
Ranked among companies with meaningful ROE % only.
CRMD' s ROE % Range Over the Past 10 Years
Min: -678.23  Med: -126.09 Max: -95.1
Current: -125.91
-678.23
-95.1
ROA % -107.31
CRMD's ROA % is ranked lower than
87% of the 991 Companies
in the Global Biotechnology industry.

( Industry Median: -30.78 vs. CRMD: -107.31 )
Ranked among companies with meaningful ROA % only.
CRMD' s ROA % Range Over the Past 10 Years
Min: -507.14  Med: -189.63 Max: -83.53
Current: -107.31
-507.14
-83.53
ROC (Joel Greenblatt) % -25324.59
CRMD's ROC (Joel Greenblatt) % is ranked lower than
92% of the 951 Companies
in the Global Biotechnology industry.

( Industry Median: -362.00 vs. CRMD: -25324.59 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CRMD' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -53119.48  Med: -39827.19 Max: -25220.83
Current: -25324.59
-53119.48
-25220.83
3-Year EBITDA Growth Rate 5.20
CRMD's 3-Year EBITDA Growth Rate is ranked higher than
55% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 0.80 vs. CRMD: 5.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CRMD' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -66.6  Med: 5.2 Max: 30.3
Current: 5.2
-66.6
30.3
3-Year EPS without NRI Growth Rate -2.00
CRMD's 3-Year EPS without NRI Growth Rate is ranked higher than
51% of the 554 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. CRMD: -2.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CRMD' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -68.4  Med: -2 Max: 24.6
Current: -2
-68.4
24.6
GuruFocus has detected 3 Warning Signs with Cormedix Inc $CRMD.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CRMD's 30-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:VICL, OTCPK:DDRT, NAS:PTIE, NAS:OCRX, OTCPK:EMIS, OTCPK:BIOAF, OTCPK:PXRB, NAS:THLD, NAS:EARS, OTCPK:RGRX, OTCPK:BLEVF, OTCPK:IPATF, NAS:VKTX, NAS:CSBR, OTCPK:BNHLF, NAS:DMPI, NAS:ONS, NAS:TRPX, OTCPK:DMCAF, NAS:MIRN » details
Traded in other countries:19K.Germany,
Headquarter Location:USA
Cormedix Inc is a commercial-stage biopharmaceutical company. It focuses on development and commercializing prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases.

Cormedix Inc was organized as a Delaware corporation on July 28, 2006 under the name Picton Holding Company, Inc. and changed it to CorMedix Inc. on January 18, 2007. The Company develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Its principal product under development includes CRMD003, an antimicrobial/anticoagulant solution applied in the prevention of catheter related bloodstream infections and maintenance of catheter patency in central venous catheters used for vascular access in hemodialysis patients. Its products also include CRMD004, a pressure sensitive gel that is in pre-clinical Phase.

Ratios

vs
industry
vs
history
PB Ratio 1.74
CRMD's PB Ratio is ranked higher than
81% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: 3.95 vs. CRMD: 1.74 )
Ranked among companies with meaningful PB Ratio only.
CRMD' s PB Ratio Range Over the Past 10 Years
Min: 1.3  Med: 3.72 Max: 31.85
Current: 1.74
1.3
31.85
PS Ratio 94.00
CRMD's PS Ratio is ranked lower than
83% of the 701 Companies
in the Global Biotechnology industry.

( Industry Median: 11.96 vs. CRMD: 94.00 )
Ranked among companies with meaningful PS Ratio only.
CRMD' s PS Ratio Range Over the Past 10 Years
Min: 86  Med: 386.36 Max: 2810
Current: 94
86
2810
Current Ratio 3.82
CRMD's Current Ratio is ranked lower than
52% of the 981 Companies
in the Global Biotechnology industry.

( Industry Median: 4.10 vs. CRMD: 3.82 )
Ranked among companies with meaningful Current Ratio only.
CRMD' s Current Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.64 Max: 20.26
Current: 3.82
0.1
20.26
Quick Ratio 3.80
CRMD's Quick Ratio is ranked higher than
50% of the 980 Companies
in the Global Biotechnology industry.

( Industry Median: 3.80 vs. CRMD: 3.80 )
Ranked among companies with meaningful Quick Ratio only.
CRMD' s Quick Ratio Range Over the Past 10 Years
Min: 0.1  Med: 4.53 Max: 19.89
Current: 3.8
0.1
19.89
Days Inventory 155.26
CRMD's Days Inventory is ranked lower than
58% of the 459 Companies
in the Global Biotechnology industry.

( Industry Median: 131.03 vs. CRMD: 155.26 )
Ranked among companies with meaningful Days Inventory only.
CRMD' s Days Inventory Range Over the Past 10 Years
Min: 72.28  Med: 246.36 Max: 480.56
Current: 155.26
72.28
480.56
Days Sales Outstanding 124.39
CRMD's Days Sales Outstanding is ranked lower than
79% of the 625 Companies
in the Global Biotechnology industry.

( Industry Median: 64.26 vs. CRMD: 124.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
CRMD' s Days Sales Outstanding Range Over the Past 10 Years
Min: 19.55  Med: 259.75 Max: 549.24
Current: 124.39
19.55
549.24
Days Payable 1.00
CRMD's Days Payable is ranked lower than
97% of the 432 Companies
in the Global Biotechnology industry.

( Industry Median: 54.41 vs. CRMD: 1.00 )
Ranked among companies with meaningful Days Payable only.
CRMD' s Days Payable Range Over the Past 10 Years
Min: 1  Med: 1667.28 Max: 1955.44
Current: 1
1
1955.44

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -34.50
CRMD's 3-Year Average Share Buyback Ratio is ranked lower than
81% of the 610 Companies
in the Global Biotechnology industry.

( Industry Median: -12.00 vs. CRMD: -34.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CRMD' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -137  Med: -34.5 Max: -13.3
Current: -34.5
-137
-13.3

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.96
CRMD's Price-to-Net-Cash is ranked higher than
88% of the 535 Companies
in the Global Biotechnology industry.

( Industry Median: 7.66 vs. CRMD: 1.96 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CRMD' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1.87  Med: 3.98 Max: 35.14
Current: 1.96
1.87
35.14
Price-to-Net-Current-Asset-Value 1.74
CRMD's Price-to-Net-Current-Asset-Value is ranked higher than
90% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 7.30 vs. CRMD: 1.74 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CRMD' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 1.67  Med: 3.59 Max: 31.74
Current: 1.74
1.67
31.74
Price-to-Tangible-Book 1.74
CRMD's Price-to-Tangible-Book is ranked higher than
85% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: 4.93 vs. CRMD: 1.74 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CRMD' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.66  Med: 3.6 Max: 31.24
Current: 1.74
1.66
31.24
Price-to-Median-PS-Value 0.24
CRMD's Price-to-Median-PS-Value is ranked higher than
90% of the 667 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. CRMD: 0.24 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CRMD' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.97 Max: 6.44
Current: 0.24
0.23
6.44
Earnings Yield (Greenblatt) % -194.82
CRMD's Earnings Yield (Greenblatt) % is ranked lower than
96% of the 989 Companies
in the Global Biotechnology industry.

( Industry Median: -7.96 vs. CRMD: -194.82 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CRMD' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -757.3  Med: -46.8 Max: -4.4
Current: -194.82
-757.3
-4.4

More Statistics

Revenue (TTM) (Mil) $0.22
EPS (TTM) $ -0.71
Beta2.42
Short Percentage of Float8.64%
52-Week Range $0.36 - 3.26
Shares Outstanding (Mil)59.34

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1 5
EPS ($) -0.61 -0.36 -0.30
EPS without NRI ($) -0.61 -0.36 -0.30
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CRMD

Headlines

Articles On GuruFocus.com
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 
Uncovering Value in the Metals and Mining Sector Jun 26 2017 
Boeing Outshines Airbus at the Paris Air Show Jun 26 2017 
Seeking Value in China: Great Wall Motor Jun 26 2017 
Vaccine Small-Cap Just Took a Big Step Forward Jun 26 2017 
Annaly Capital Management: Attractive 9.5% Dividend Yield, but Interest Rates Are a Major Risk Jun 25 2017 
Never a Better Time to Pile on Chipotle Jun 25 2017 
Oracle Slowly Gaining Momentum on the Cloud Front Jun 26 2017 
Boeing Takes Lead Over Airbus With $30 Billion Worth of Orders on Day 1 of Paris Air Show Jun 25 2017 
Berkshire Hathaway’s Recent Investment: Home Capital Group Jun 25 2017 

More From Other Websites
CorMedix Inc. Appoints Mehmood Khan, M.D. and Steven Lefkowitz to its Board of Directors Jun 26 2017
Implied Volatility Surging for CorMedix (CRMD) Stock Options Jun 23 2017
ETFs with exposure to CorMedix, Inc. : June 16, 2017 Jun 16 2017
CorMedix Inc. to Showcase Its Taurolidine-Based Development Pipeline at Research and Development Day Jun 14 2017
CorMedix Inc. Announces Changes to Board of Directors Jun 12 2017
ETFs with exposure to CorMedix, Inc. : May 26, 2017 May 26 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... May 26 2017
CorMedix, Inc. :CRMD-US: Earnings Analysis: Q1, 2017 By the Numbers : May 12, 2017 May 12 2017
CorMedix Inc. Reports First Quarter Financial Results and Provides Business Update May 10 2017
CorMedix Inc. Demonstrates Sensitivity of Emerging Global Health Threat Candida auris to Taurolidine May 09 2017
CorMedix Inc. to Report First Quarter 2017 Financial Results and Provide Business Update May 05 2017
CorMedix Inc. Announces Closing of Public Offering of Common Stock and Warrants and Underwriter's... May 03 2017
CorMedix Inc. Increases Previously Announced Public Offering to $12.1 Million Apr 28 2017
CorMedix Inc. Announces $10 Million Underwritten Public Offering Apr 27 2017
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of... Apr 24 2017
CorMedix Inc. Reports Update on Neutrolin(R) Phase 3 LOCK-IT 100 Clinical Trial Apr 20 2017
CorMedix Inc. Secures First European Commercial Collaboration for Neutrolin(R) Apr 12 2017
ETFs with exposure to CorMedix, Inc. : April 10, 2017 Apr 10 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}